Lymph Node — Immune Filter and Cancer Staging Marker

Lymph nodes are vital components of the lymphatic system, a network of vessels that drains excess interstitial fluid, known as lymph, from tissues back into the blood circulation. Distributed in clusters along these pathways—notably in the neck, underarms, chest, abdomen, and groin—nodes act as biological filters containing specialised lymphocytes and macrophages.

When cancer cells detach from a solid tumour, they frequently enter neighbouring lymphatic channels and lodge in the closest draining lymph nodes. The presence or absence of malignant cells in regional lymph nodes provides clinicians with essential prognostic information, forming the basis of the 'N' category in the TNM staging system.

Knowing the status of your lymph nodes directly shapes your cancer care pathway. Node-negative cancer indicates the disease has remained confined locally, which often requires less aggressive interventions. Conversely, node-positive disease shows that cancer cells have entered the lymphatic network, which usually warrants broader treatment—such as regional radiotherapy, surgical clearance, or systemic therapies like chemotherapy—to eradicate microscopic cells throughout the body and prevent distant spread.

Lymph nodes are assessed through physical examination and imaging such as ultrasound, CT, MRI, and PET scans. Pathological evaluation involves fine-needle aspiration, core biopsy, sentinel lymph node biopsy (SLNB), or regional lymphadenectomy. Pathologists examine harvested nodes using haematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) to detect micro-metastases.

Lymph node evaluation is fundamental in almost all solid tumours, including breast cancer (axillary nodes), melanoma, colorectal cancer (mesenteric nodes), lung cancer (mediastinal nodes), head and neck tumours (cervical nodes), and prostate or gynaecological cancers (pelvic and retroperitoneal nodes). It is also central to diagnosing lymphomas.

If cancer is found in regional lymph nodes, treatment intensity typically increases. Surgical plans may expand to include a wider lymph node dissection. Radiation therapy fields are frequently extended to encompass regional nodal basins, and systemic therapies—such as adjuvant chemotherapy, targeted therapy, or immunotherapy—are commonly recommended to eliminate undetected circulating cells.